Incyte
Stock Forecast, Prediction & Price Target
Incyte (INCY) stock Price Target by analysts
$106.17
Potential upside: 24.22%
Incyte price prediction
What is Incyte stock analysts` prediction?
Incyte stock forecast: Based on 6 Wall Street analysts` predicted price targets for Incyte in the last 3 months, the avarage price target is $106.17, with a high forecast of $NaN. The average price target represents a 24.22% change from the last price of $85.46.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Incyte stock Price Target by analysts
Full breakdown of analysts given Incyte price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
David Lebowitz Citigroup | 0% 0/2 | 11 months ago | $97 13.50% upside | $73.6 | StreetInsider | Previous targets (1) |
Jay Olson Oppenheimer | 0% 0/4 | 11 months ago | $82 -4.04% downside | $73.6 | TheFly | Previous targets (3) |
Aaron Kessler Seaport Global | 0% 0/1 | 11 months ago | $200 134.02% upside | $73 | Benzinga | Previous targets (0) |
Kelly Shi Jefferies | 0% 0/1 | 11 months ago | $84 -1.70% downside | $73.6 | StreetInsider | Previous targets (0) |
Tazeen Ahmad Bank of America Securities | 0% 0/2 | 11 months ago | $90 5.31% upside | $73.6 | StreetInsider | Previous targets (1) |
Andy Chen Wolfe Research | 0% 0/1 | 12 months ago | $84 -1.70% downside | $66.1 | TheFly | Previous targets (0) |
Tazeen Ahmad Bank of America Securities | 0% 0/2 | about 1 year ago | $68 -20.43% downside | $63.56 | StreetInsider | Previous targets (1) |
Salveen Richter Goldman Sachs | 0% 0/2 | about 1 year ago | $60 -29.79% downside | $63.56 | StreetInsider | Previous targets (1) |
David Lebowitz Citigroup | 0% 0/2 | about 1 year ago | $92 7.65% upside | $62.16 | TheFly | Previous targets (1) |
Brian Abrahams RBC Capital | 0% 0/1 | about 1 year ago | $66 -22.77% downside | $65.7 | TheFly | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/4 | about 1 year ago | $81 -5.21% downside | $68.57 | TheFly | Previous targets (3) |
Evan Seigerman BMO Capital | 50% 1/2 | about 1 year ago | $48 -43.83% downside | $60.87 | StreetInsider | Previous targets (1) |
James Shin Deutsche Bank | 0% 0/1 | over 1 year ago | $55 -35.64% downside | $58.2 | TheFly | Previous targets (0) |
Evan David Seigerman BMO Capital | 100% 1/1 | over 1 year ago | $52 -39.15% downside | $52.05 | StreetInsider | Previous targets (0) |
Jasper Hellweg Argus Research | 0% 0/1 | over 1 year ago | $70 -18.09% downside | $50.48 | TheFly | Previous targets (0) |
Unknown Cowen & Co. | N/A | over 2 years ago | $100 17.01% upside | $80.38 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $75 -12.23% downside | $79.74 | Benzinga | N/A |
Jay Olson Oppenheimer | 0% 0/4 | about 3 years ago | $98 14.67% upside | $73.99 | Pulse 2.0 | Previous targets (3) |
Unknown Leerink Partners | N/A | about 3 years ago | $63 -26.28% downside | $81.36 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 3 years ago | $76 -11.06% downside | $78.94 | Benzinga | N/A |
Evan Seigerman BMO Capital | 50% 1/2 | over 3 years ago | $75 -12.23% downside | $70.07 | StreetInsider | Previous targets (1) |
Michael Schmidt Guggenheim | 0% 0/1 | over 3 years ago | $104 21.69% upside | $73.97 | TheFly | Previous targets (0) |
Salveen Richter Goldman Sachs | 0% 0/2 | almost 4 years ago | $136 59.13% upside | $66.74 | StreetInsider | Previous targets (1) |
Jay Olson Oppenheimer | 0% 0/4 | almost 4 years ago | $109 27.54% upside | $66.79 | StreetInsider | Previous targets (3) |
Alethia Young Cantor Fitzgerald | 100% 1/1 | almost 4 years ago | $79 -7.55% downside | $65.56 | TheFly | Previous targets (0) |
Aydin Huseynov Ladenburg Thalmann & Co. | 0% 0/1 | about 4 years ago | $89 4.14% upside | $69.78 | TheFly | Previous targets (0) |
Incyte Financial Estimates
Incyte Revenue Estimates
Incyte EBITDA Estimates
Incyte Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $2.98B N/A | $3.39B 13.67% | $3.69B 8.86% | Avg: $4.51B Low: $4.43B High: $4.74B avg. 22.18% | Avg: $5.00B Low: $4.78B High: $5.22B avg. 10.75% | Avg: $5.35B Low: $5.12B High: $5.59B avg. 7.08% | Avg: $5.58B Low: $5.34B High: $5.83B avg. 4.24% |
Net Income
% change YoY
| $948.58M N/A | $340.66M -64.08% | $597.59M 75.42% | Avg: $955.27M Low: $700.37M High: $1.33B avg. 59.85% | Avg: $1.21B Low: $858.52M High: $1.59B avg. 26.72% | Avg: $1.61B Low: $1.52B High: $1.71B avg. 33.53% | Avg: $1.81B Low: $1.71B High: $1.92B avg. 12.42% |
EBITDA
% change YoY
| $611.16M N/A | $631.52M 3.33% | $919.42M 45.58% | Avg: $698.63M Low: $686.34M High: $733.94M avg. -24.01% | Avg: $773.77M Low: $740.23M High: $808.89M avg. 10.75% | Avg: $828.59M Low: $792.67M High: $866.19M avg. 7.08% | Avg: $863.80M Low: $826.35M High: $903.00M avg. 4.24% |
EPS
% change YoY
| $4.3 N/A | $1.53 -64.41% | $2.67 74.50% | Avg: $4.17 Low: $3.1 High: $5.9 avg. 56.28% | Avg: $5.29 Low: $3.8 High: $7.06 avg. 26.72% | Avg: $7.15 Low: $6.75 High: $7.58 avg. 35.30% | Avg: $8.04 Low: $7.59 High: $8.52 avg. 12.42% |
Operating Expenses
% change YoY
| $2.23B N/A | $2.59B 16.16% | $2.82B 8.63% | Avg: $1.14B Low: $1.12B High: $1.20B avg. -59.39% | Avg: $1.26B Low: $1.21B High: $1.32B avg. 10.75% | Avg: $1.35B Low: $1.29B High: $1.41B avg. 7.08% | Avg: $1.41B Low: $1.35B High: $1.48B avg. 4.24% |
FAQ
What is Incyte stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 33.13% in 2025-2028.
We have gathered data from 12 analysts. Their low estimate is 700.37M, average is 955.27M and high is 1.33B.
What is Incyte stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 11.06% in 2025-2028.
We have gathered data from 17 analysts. Their low revenue estimate is $4.43B, average is $4.51B and high is $4.74B.
What is Incyte stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 32.68% in 2025-2028.
We have gathered data from 12 analysts. Their low earnings per share estimate is $3.1, average is $4.17 and high is $5.9.
What is the best performing analyst?
In the last twelve months 6 analysts have been covering Incyte stock. The most successful analyst is David Lebowitz.